# A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

> **NCT04003389** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 1831 (actual)

## Conditions studied

- Hot Flashes

## Interventions

- **DRUG:** fezolinetant
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04003389
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-10
- **Primary completion:** 2022-01-04
- **Final completion:** 2022-01-04
- **Target enrollment:** 1831 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003389, "A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04003389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*